by BMJ Journals
Preclinical evidence identifies human epidermal growth factor receptor 2 (HER2) as a promising candidate for chimeric antigen receptor (CAR) T-cell therapy in solid cancers but it is best to...
by Alex Kadhim
Researchers have discovered a significant function of the Id3 protein in the persistence and operational capabilities of tissue-infiltrating alloreactive T cells, offering insights that could...
by Nature Medicine
Off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells are a more affordable and safer alternative to autologous anti-CD19 CAR T cells for the treatment of CD19+ B cell malignancies.
by ASH Publications
All patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) have the potential to develop veno-occlusive disease (VOD), but researchers have found the incidence and risk...
by March 2024 Advocacy Update
Advocacy at the Tandem Meetings Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
by April 2024 Advocacy Update
CMS Expands Coverage for Allogeneic HSCT in MDS Patients